Research article · 15 Apr 2026
Conference abstractPublished 6 Jul 2017
Application of precursor stem cells and targeted organ-specific peptide therapy for kidney regeneration in patients with Chronic Kidney Disease
Stellar Bio molecular Research (SBR) and FCTI, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic Kidney Disease (CKD) is characterized by progressive deterioration of renal function due to loss of functioning nephrons. In spite of available treatments, CKD is still considered as irreversible, with gradually worsening condition that ultimately results in End-Stage Renal Failure (ESRF). Such situation urges to seek for new advanced therapeutic modalities that are able to restore renal function or at least substantially slow down the progression of CKD. Recent research and studies has shown that the most promising opportunity to restore nephron functionality is stem cell therapy. Due to morphological complexity of the kidneyâÂ?Â?s ultrastructure the available options of autologous stem cell therapy has proven its failure to restore the anatomy and functionality of nephron. On the other hand embryonic and induced pluripotent stem cells have multiple unsolved safety issues. Latest scientific developments demonstrate that fetal precursor stem cells transplantation is the safest and most reliable method of renal cellular pool replacement in patients with CKD. In our study, we present data on efficacy of combination of precursor stem cells (FCTI) and targeted organ-specific peptides (SBI, MF+, Germany) in patients with CKD. Results of stem cell implantation were evaluated 6 months and 1 year after the procedure. Certain improvements of parameters of renal function test and downstaging of CKD, depending on the stage of the disease, were noted. There were no adverse reactions observed in treated patients. Precursor stem cells and organ-specific peptides (SBI, MF+, Germany) in management of CKD is a promising therapeutic modality and requires further detailed analysis and continued clinical trials.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Dmitry Klokol”
